Hemophilia affects an estimated 40,000 people in the U.S. and remains one of the highest-cost rare conditions for plan sponsors. Annual treatment costs can range from more than $200,000 to nearly $900,000 per patient, and for individuals who develop inhibitors, total spend can exceed $1 million annually. Beyond the magnitude of these costs, sponsors must contend with wide variability in utilization, outcomes, and long‑term risk across a small population.
As new therapeutic options emerge — including gene therapy, non-factor biologics, and extended half-life factor products — digital enablement offers plan sponsors an essential pathway to improve care coordination, enhance outcomes, and reduce inequities across the hemophilia population.
The persistent clinical and economic burden
Even with improved treatment options, the complexity of managing hemophilia remains high. Depending on severity, age, and inhibitor status, annual costs vary widely, driven in large part by the intensity of prophylactic therapy. The broad cost range of more than $200,000 to nearly $900,000 highlights the need for better tools to optimize therapy and minimize waste.
At the same time, outcomes are not equitable. Hemophilia‑related mortality has declined nearly 50% since 1999, yet Black men still experience death rates 30% higher and die about a decade earlier than white men. These gaps reflect longstanding structural inequities affecting diagnosis, access to specialty care, and treatment continuity.
How digital enablement is transforming hemophilia care
Digital enablement in hemophilia care does not begin with advanced technology — it begins with removing friction from essential moments in the patient journey. Today, digital tools play a critical role in supporting access, continuity, and engagement for individuals managing a complex, lifelong condition.
For patients receiving subcutaneous therapies such as Hemlibra® and Hympavzi™, digital refill capabilities through web and mobile platforms offer a more convenient, reliable way to manage ongoing treatment. These tools allow patients to order medications on their own schedule, helping reduce delays and administrative burden while supporting consistent therapy.
Importantly, digital engagement at the point of refill also enables the capture of meaningful clinical and non-clinical updates. Changes in therapy needs, health status, or potential barriers to care can be identified early and routed to clinical teams for appropriate follow‑up. While this is not real‑time monitoring, it represents a practical, scalable way to support proactive care management within today’s specialty pharmacy model.
As hemophilia therapies and delivery models continue to evolve, these foundational digital capabilities create a platform for more connected, responsive care — without overcomplicating the patient experience.
What digital enablement means for plan sponsors
For plan sponsors managing a condition as clinically complex and financially variable as hemophilia, digital enablement is less about cutting‑edge technology and more about operational consistency, visibility, and member experience.
Today’s digital specialty pharmacy tools help plan sponsors:
- Support adherence through convenience, by enabling patients to manage refills digitally for select therapies
- Identify potential care gaps earlier, by capturing patient‑reported needs and clinical changes during refill interactions
- Route members to appropriate clinical support, when digital assessments indicate follow‑up is needed
- Improve affordability navigation, by making patients aware of copay assistance options and allowing them to manage payment methods digitally
- Enhance member experience and satisfaction, through self‑service options that align with patient preferences
While advanced capabilities such as real‑time monitoring and virtual clinical visits continue to emerge across the broader health care landscape, today’s digital enablement already delivers measurable value. Studies and internal experience show that patients who engage with these tools demonstrate higher adherence and satisfaction — outcomes that directly support plan sponsor goals.
In hemophilia care, digital enablement is not an all‑or‑nothing proposition. Incremental, well‑designed tools can drive meaningful impact when applied at the right moments in the care journey.
Digital enablement as a driver of health equity
Digital tools are critical in addressing the inequities that persist across hemophilia care.
Expanding access across geographies
Telemedicine helps bridge gaps for patients living far from specialized treatment centers. Digital networks have already demonstrated their ability to connect local providers with hemophilia specialists in real time, reducing dangerous delays in care.
Supporting underserved populations
Disparities disproportionately affect Black, Hispanic/Latino, Indigenous, immigrant, LGBTQIA+, and low-income individuals. Digital platforms can help mitigate these gaps by offering scalable multilingual education, culturally informed engagement, and consistent clinical support regardless of location.
Data-driven insights into inequities
Digital health equity tools provide critical insights into disparities by race, ethnicity, geography, and social determinants. Platforms designed for this purpose offer accessible ways to track and analyze inequities across conditions and populations, empowering organizations to design more targeted interventions.
Leverage the benefits of digital enablement in hemophilia care
As transformative therapies reshape hemophilia care, digital infrastructure increasingly separates what is possible from what is achievable today. Many programs still operate with fragmented data, episodic engagement, and limited insight into adherence, outcomes, and disparities — constraining the real-world impact of advanced treatments.
The future state is a digitally enabled model of care, where remote monitoring, telehealth, personalized engagement, and equity-focused analytics provide continuous visibility and proactive intervention. For plan sponsors, moving from today’s disconnected digital environment to a digital-first approach is a strategic shift that supports better outcomes, more responsible cost management, and equitable access to high-quality hemophilia care for every member.
This article was created with the assistance of AI tools. It was reviewed, edited, and fact-checked by Evernorth’s editorial team and subject matter experts.
Evernorth’s Accredo Specialty Pharmacy raises the standard in specialty pharmacy, delivering care beyond the prescription and additive savings beyond the trend. Through our pharmacy model, plan sponsors can count on competitive specialty drug pricing and access to the specialty therapies your members need. We provide condition- and drug-focused expertise that prepares you for what’s ahead while driving the most value for you now. Our pharmacy engine propels savings to you and delivers well-being support for your members at no cost.
